Background: Treatment of systemic lupus erythematosus (SLE) is tailored according to the intensity SLE disease activity and aims achieve remission. Current definitions remission categories are mostly based on Disease Activity Index (SLEDAI), which has important limitations. The Score (SLE-DAS) a validated continuous score with higher accuracy in measuring sensitivity-to-change as compared SLEDA...

OBJECTIVES TO COMPARE TWO MEASURES OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) RESPONSE: the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) and the Systemic Lupus Responder Index (SRI) against a clinician's assessment of improvement. METHODS Ninety-one lupus patients were identified with two visits at which Systemic Lupus Erythematosus Disease Activity Index (...

OBJECTIVES To determine the most appropriate indices to evaluate the disease activity and damage in patients with sytemic lupus erythematosus (SLE). METHODS A systematic literature search was performed to identify validation studies of indices used to evaluate disease activity and damage. We collected information for each instrument on every aspect of validation including feasibility, reliabi...

B cells play an important role in the pathogenesis of systemic lupus erythematosus (SLE), so the safety and activity of anti-B cell immunotherapy with the humanized anti-CD22 antibody epratuzumab was evaluated in SLE patients. An open-label, single-center study of 14 patients with moderately active SLE (total British Isles Lupus Assessment Group (BILAG) score 6 to 12) was conducted. Patients re...

INTRODUCTION High mobility group box 1 protein (HMGB1) is a nuclear DNA binding protein acting as a pro-inflammatory mediator following extracellular release. HMGB1 has been increasingly recognized as a pathogenic mediator in several inflammatory diseases. Elevated serum levels of HMGB1 have been detected in autoimmune diseases including Systemic lupus erythematosus (SLE). However, the local ex...

OBJECTIVES To assess the prevalence of antibodies to human fibronectin (anti-Fn) in sera of patients with certain connective tissue diseases and to determine their association with disease activity and the pattern of organ involvement in patients with systemic lupus erythematosus (SLE). METHODS A capture enzyme linked immunosorbent assay (ELISA) was developed to quantify anti-Fn antibodies in...

Background: We developed and validated two continuous interferon-stimulated gene (ISG) expression scores (IFN-Score-A IFN-Score-B) that predict clinical outcomes in SLE. IFN-Score-A includes ISGs typically present a global interferon signature while IFN-Score-B additional potentially responsive to multiple IFN subtypes [1]. have previously shown these associate with treatment response following...

INTRODUCTION In our present single-center pilot study, umbilical cord (UC)-derived mesenchymal stem cells (MSCs) had a good safety profile and therapeutic effect in severe and refractory systemic lupus erythematosus (SLE). The present multicenter clinical trial was undertaken to assess the safety and efficacy of allogeneic UC MSC transplantation (MSCT) in patients with active and refractory SLE...

Background Systemic Lupus erythematous (SLE) is an autoimmune disease which characterized by remission and flares. Experimental studies demonstrate that sun exposure can trigger immunomodulatory response, however, there lacking of strong epidemiologic data regarding its role in triggering SLE flare. Malaysia has a tropical climate hence get more to the sun. Objectives To determine correlations ...